Last updated: 2026-10-13 16:36:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Stevanato Group S.p.A. (STVN) operates in the -- sector and is listed on NYSE. The stock is currently priced at $18.93, with a market capitalisation of $5.30B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $12.89 to $27.99. This page covers its latest market performance, valuation, price trends and company information.
$5.30B | |
$19.20 | |
$36.30 | |
$12.89 | |
$19.24 | |
86.36K | |
371.72K | |
-- | |
$27.99 | |
$12.89 | |
-- | |
-- |
Stevanato Group S.p.A. (STVN) is currently trading at $18.93 as of 2026-10-13 16:20:06, down 1.61% ($0.31) from the previous close of $19.24
During today's regular trading session, STVN has traded between $12.89 and $36.30, with a trading volume of 86.36K shares. The current price is near the lower end of today's range.
Over the past seven days, Stevanato Group S.p.A. (STVN) moved from $20.20 to $18.93, representing a decline of 6.29% ($1.27).
The stock traded between $18.85 and $20.91 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 309.36 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 40.0%
STVN is currently trading at $18.93, placing it 40.0% of the way from its 52-week low of $12.89 to its 52-week high of $27.99. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Stevanato Group is a provider of glass and polymer drug containment, drug delivery, and diagnostic solutions to the pharmaceutical and life sciences industries. The company operates through two segments: a Biopharmaceutical and Diagnostic Solutions segment, which offers an integrated, end-to-end portfolio of products, processes, and services spanning the full drug lifecycle; and an Engineering segment, which designs, develops, and manufactures advanced machinery for pharmaceutical manufacturing, covering visual inspection, assembly and packaging, glass converting, and serialization. Stevanato's revenue is geographically diversified, with approximately 60% of sales generated in Europe, the Middle East, and Africa, 30% in North America, 8% in Asia-Pacific, and 2% in South America.
| Employees | 5795 |
| Exchange | NYSE |
| Company Website |
Eligible investors can buy real shares of Stevanato Group S.p.A. (STVN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.